GENTAMICIN SULFATE  - gentamicin sulfate ointment 
E. FOUGERA & CO., A division of Fougera Pharmaceuticals Inc.

----------

DESCRIPTION:

Gentamicin sulfate is a water soluble antibiotic of the aminoglycoside group.

Gentamicin Sulfate Ophthalmic Ointment USP is a sterile ointment for topical ophthalmic use. Each gram contains gentamicin sulfate (equivalent to 3 mg gentamicin) in a base of white petrolatum and mineral oil.

Gentamicin is obtained from cultures of Micromonospora purpurea. Gentamicin sulfate is a mixture of the sulfate salts of gentamicin C1, C2 and C1A. All three components appear to have similar antimicrobial activities. Gentamicin sulfate occurs as a white powder and is soluble in water and insoluble in alcohol. The structural formula is as follows:

Structural Formula

CLINICAL PHARMACOLOGY:

Microbiology:  Gentamicin sulfate is active in vitro against many strains of the following microorganisms:

    Staphylococcus aureus, Staphylococcus epidermidis,

    Streptococcus pyogenes, Streptococcus pneumoniae,

    Enterobacter aerogenes, Escherichia coli, Haemophilus influenzae,

    Klebsiella pneumoniae, Neisseria gonorrhoeae,

    Pseudomonas aeruginosa, and Serratia marcescens.

INDICATIONS AND USAGE:

Gentamicin Sulfate Ophthalmic Ointment is indicated in the topical treatment of ocular bacterial infections, including conjunctivitis, keratitis, keratoconjunctivitis, corneal ulcers, blepharitis, blepharoconjunctivitis, acute meibomianitis, and dacryocystitis caused by susceptible strains of the following microorganisms:

    Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Streptococcus pneumoniae, Enterobacter aerogenes, Escherichia coli, Haemophilus influenzae, Klebsiella pneumoniae, Neisseria gonorrhoeae, Pseudomonas aeruginosa, and Serratia marcescens.

CONTRAINDICATIONS:

Gentamicin Sulfate Ophthalmic Ointment is contraindicated in patients with known hypersensitivity to any of the components.

WARNINGS:

NOT FOR INJECTION INTO THE EYE.  Gentamicin Sulfate Ophthalmic Ointment is not for injection.  It should never be injected subconjunctivally, nor should it be directly introduced into the anterior chamber of the eye.

PRECAUTIONS

General:

Prolonged use of topical antibiotics may give rise to overgrowth of non-susceptible organisms including fungi. Bacterial resistance to gentamicin may also develop. If purulent discharge, inflammation or pain becomes aggravated, the patient should discontinue use of the medication and consult a physician.

If irritation or hypersensitivity to any component of the drug develops, the patient should discontinue use of this preparation, and appropriate therapy should be instituted.

Ophthalmic ointments may retard corneal healing.

Information For Patients:

To avoid contamination, do not touch tip of container to the eye, eyelid, or any surface.

Carcinogenesis, Mutagenesis and Impairment of Fertility:

There are no published carcinogenicity or impairment of fertility studies on gentamicin.  Aminoglycoside antibiotics have been found to be non-mutagenic.

Pregnancy:

Teratogenic effects - Pregnancy Category C.  Gentamicin has been shown to depress body weights, kidney weights, and median glomerular counts in newborn rats when administered systemically to pregnant rats in daily doses approximately 500 times the maximum recommended ophthalmic human dose.  There are no adequate and well-controlled studies in pregnant women.  Gentamicin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Pediatric Use:

Safety and effectiveness in neonates have not been established.

ADVERSE REACTIONS:

Bacterial and fungal corneal ulcers have developed during treatment with gentamicin ophthalmic preparations.

The most frequently reported adverse reactions are ocular burning and irritation upon drug instillation, non-specific conjunctivitis, conjunctival epithelial defects, and conjunctival hyperemia.

Other adverse reactions which have occurred rarely are allergic reactions, thrombocytopenic purpura, and hallucinations.

DOSAGE AND ADMINISTRATION:

Apply a small amount (about 1/2 inch) to the affected eye(s) two to three times a day.

HOW SUPPLIED:

Gentamicin Sulfate Ophthalmic Ointment USP (equivalent to 3 mg gentamicin) is supplied as follows:

NDC 0168-0044-38 3.5 gram tubes

Store at 25oC (77oF); excursions permitted to 15-30oC (59-86oF)

[see USP Controlled Room Temperature].

E. FOUGERA & CO.

A division of Nycomed US Inc.

Melville, New York 1174

I24438B

R10/07

#82

PRINCIPAL DISPLAY PANEL - CARTON

Carton Label


NDC 0168-0044-38

Fougera®

Rx only

GENTAMICIN SULFATE

OPHTHALMIC OINTMENT

USP STERILE

Gentamicin Sulfate, USP equivalent

to 3 mg gentamicin per gram.

WARNING: Keep out

of reach of children.

Net Wt. 3.5g (1/8 Oz)

PRINCIPAL DISPLAY PANEL - CONTAINER

Container Label

NDC 0168-0044-38

Fougera®

GENTAMICIN

SULFATE

OPHTHALMIC

OINTMENT, USP

STERILE

Rx only

Gentamicin Sulfate,

USP equivalent to 3 mg

gentamicin per gram.

Each gram contains:

Gentamicin sulfate, USP

equivalent to 3 mg gentamicin

base, in a base of white

petrolatum and mineral oil.

WARNING: Keep out

of reach of children.


GENTAMICIN SULFATE 
gentamicin sulfate ointment
Product Information
Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:0168-0044
Route of AdministrationOPHTHALMICDEA Schedule    
Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
GENTAMICIN SULFATE (GENTAMICIN) GENTAMICIN3 mg  in 1 g
Inactive Ingredients
Ingredient NameStrength
MINERAL OIL 
PETROLATUM 
Product Characteristics
Color    Score    
ShapeSize
FlavorImprint Code
Contains    
Packaging
#Item CodePackage DescriptionMultilevel Packaging
1NDC:0168-0044-381 TUBE in 1 CARTONcontains a TUBE
13.5 g in 1 TUBEThis package is contained within the CARTON (0168-0044-38)

Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
ANDAANDA06502407/30/200407/31/2009

Labeler - E. FOUGERA & CO., A division of Fougera Pharmaceuticals Inc. (043838424)
Establishment
NameAddressID/FEIOperations
Fougera Pharmaceuticals Inc.174491316MANUFACTURE
Establishment
NameAddressID/FEIOperations
Fougera Pharmaceuticals Inc.043838424ANALYSIS

Revised: 11/2012 E. FOUGERA & CO., A division of Fougera Pharmaceuticals Inc.